noageing's  Instablog

Send Message
Yury has closed the largest life sciences deal in Russia and CIS that was focused on cancer drugs. His primary goal is to defeat cancer, heart disease and neurodegenerative diseases and to extend healthy and youthful life span of a human by twofold or more. To achieve this Yury is investing in... More
  • BioTime research report agenda 0 comments
    Jan 4, 2011 3:46 AM | about stocks: BTIM-RETIRED, BTIM.OB-RETIRED

    I just made 1,4% on BioTime Inc. today, could have made more but I think that BioTime Inc. will grow substantially over the next decades. BioTime technology is next generation technology, that is much safer than what Geron has. I think it is the #1 company in stem cells/ regenerative medicine globally as of today that is best positioned to cure cancer, heart disease, neurodegenerative diseases and ageing as a regulation disease. CEO is brilliant, one of the founders of stem cell industry. Since Mike West joined the company as a CEO in 2007 BioTime has grown from $0.20 per share to amazing $8.9 per share and capitalization of $ 424.56M. One of the leading investors in BioTime is BlackRock with US$3.45 trillion assets under management. BioTime started successfully working with China as of last year: BioTime Inks Progenitor Cell Distribution Deal for China at Seeking Alpha Sun, Dec 12  
    Just this year alone the company should complete many more deals.
    BioTime, Inc. Common Stock (AMEX: BTX)
    After Hours: 8.92 0.00 (0.00%) 5:42PM EST
    Last Trade:8.92
    Trade Time:4:01PM EST
    Change: 0.59 (7.08%)
    Prev Close:8.33
    Bid:8.10 x 200
    Ask:9.50 x 5000
    1y Target Est:N/A
    Day's Range:8.36 - 9.09
    52wk Range:4.02 - 9.94
    Avg Vol (3m):255,641
    Market Cap:424.56M
    P/E (ttm):N/A
    EPS (ttm):-0.18
    Div & Yield:N/A (N/A)

    BioTime Subsidiary ReCyte Therapeutics, Inc. to Develop Therapies for Age-Related Cardiovascular and Blood Disorders Business Wire Mon 9:00AM EST
    BIOTIME INC Files SEC form 8-K, Unregistered Sale of Equity Securities, Other Events EDGAR Online Mon 8:45AM EST
    The End-of-Year Melt Up Continues Indie Research Wed, Dec 29
    BioTime, Inc. and the University of California System Sign Cell Transfer Agreement for Human Embryonic Stem Cell Lines Business Wire Wed, Dec 22
    Director Of Equity Research At RBC Capital Markets Covers Phase III Data For Multiple New Drugs; Find Out The Stocks That Investors Should Look At Wall Street Transcript Fri, Dec 17
    Breakout Stocks Chased by Smart Money at Seeking Alpha Mon, Dec 13
    China Biotech Week in Review: GSK Acquires Urology Drugmaker at Seeking Alpha Sun, Dec 12
    BioTime Inks Progenitor Cell Distribution Deal for China at Seeking Alpha Sun, Dec 12
    BIOTIME INC Files SEC form 8-K, Other Events EDGAR Online Thu, Dec 9
    BioTime Asia, Limited and Shanghai Genext Medical Technology Co., Ltd. Sign Marketing Agreement for ACTCellerate™ Cell Lines Business Wire Thu, Dec 9

    I hope you find this as interesting as I do.

    We are currently looking for the leading life sciences / stem cells analyst on the market to write a research report on BioTime Inc. Please contact me at my private e-mail:

    Kind regards,

    Yury Oreshin
    Teknoinvest Angelico Ventures
    9-105 Esseninsky boulevard
    Moscow, Russia 109439
    Cell: +79163888355 (Moscow)
    Tel: +442032879882 (London)

    Disclosure: I am long BTIM, BTIM.OB.
Back To noageing's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.